Literature DB >> 22475841

Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study.

Ralph F Bosch1, Wilhelm Kirch, Juergen-Detlef Theuer, David Pittrow, Annette Kohlhaußen, Stefan N Willich, Hendrik Bonnemeier.   

Abstract

BACKGROUND: We aimed to describe the current management of patients with atrial fibrillation (AF) by cardiologists, and to identify predicting factors for a stable disease course.
METHODS: 2753 consecutive patients with ECG-confirmed AF in the previous 12 months were documented in a 1-year observational (non-interventional) study from 616 centers. Stable disease was defined as having neither AF related intervention nor change in antiarrhythmic therapy in the previous 12 months. Stepwise selection of parameters for multivariate regression was used to identify factors for stable AF.
RESULTS: At baseline, paroxysmal AF was reported in 33.5%, persistent in 26.7%, and permanent in 39.7%; rate control alone was the prevailing antiarrhythmic strategy (64.2%). Drugs for thromboembolic prevention were administered in 93.8%, with a clear predominance of oral anticoagulants (OAC), alone or in combination with antiplatelet drugs. Electrical or pharmacological conversions were reported in 23.6%. A total of 96 (3.5%) patients in the total cohort experienced stroke, 72 patients (2.6%) TIA, and 24 (0.9%) arterial embolism. 26% were hospitalized during follow-up (0.4 events per patient), and 9.4% developed incident heart failure (42% prevalence at follow-up). The rate of stable patients was 43.4%. In the multivariate model male gender, history of stroke, and permanent (vs. persistent) AF were associated with stable disease. Conversely, the factors chronic heart failure, impaired left ventricular function, rhythm-control (vs. other), OAC and antiplatelet therapy were significantly correlated with unstable disease.
CONCLUSIONS: The relatively low proportion of stable patients and in particular, the high hospitalization and stroke rate indicate difficulties in everyday management of patients with AF.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Hospitalization; Long-term; Management; Predictors; Thromboembolic prevention, stroke

Mesh:

Substances:

Year:  2012        PMID: 22475841     DOI: 10.1016/j.ijcard.2012.03.053

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

Review 1.  Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis.

Authors:  Alessio Lilli; Andrea Di Cori; Valerio Zacà
Journal:  Clin Cardiol       Date:  2017-05-04       Impact factor: 2.882

2.  Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.

Authors:  Yutao Guo; Hao Wang; Yingchun Tian; Yutang Wang; Gregory Y H Lip
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

3.  Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF Study.

Authors:  Anselm K Gitt; Wenefrieda Smolka; Galin Michailov; Alexandra Bernhardt; David Pittrow; Thorsten Lewalter
Journal:  Clin Res Cardiol       Date:  2013-06-30       Impact factor: 5.460

4.  Gender differences in patients with atrial fibrillation.

Authors:  Ralph F Bosch; David Pittrow; Anne Beltzer; Irmtraut Kruck; Wilhelm Kirch; Annette Kohlhaussen; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-08-27

Review 5.  Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation.

Authors:  A John Camm; Fausto J Pinto; Graeme J Hankey; Felicita Andreotti; F D Richard Hobbs
Journal:  Europace       Date:  2015-07       Impact factor: 5.214

6.  Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.

Authors:  Günter Breithardt; Helmut Baumgartner; Scott D Berkowitz; Anne S Hellkamp; Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf
Journal:  Eur Heart J       Date:  2014-08-22       Impact factor: 29.983

7.  Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).

Authors:  Paulus Kirchhof; Bettina Ammentorp; Harald Darius; Raffaele De Caterina; Jean-Yves Le Heuzey; Richard John Schilling; Josef Schmitt; Jose Luis Zamorano
Journal:  Europace       Date:  2013-10-01       Impact factor: 5.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.